Review of Pharmacology and Physiology in Thrombolysis Interventions

ABSTRACT

Reperfusion therapy using thrombolytic agents has been shown to be a safe and effective treatment strategy for arterial ischemia, venous thrombosis, massive pulmonary embolism, and acute stroke. Thrombolytic agents have evolved over the course of a few decades, from nonfibrin selective to fibrin-selective agents. The development and modification of these agents have resulted in improved understanding of their pharmacologic attributes, and their effects on the complex molecular events that occur during thrombolysis goal-directed therapies. The current review focuses on the physiology and pharmacology of the thrombolytic agents that have been or are currently in use for interventional thrombolysis interventions. Attention is also given to the particular role that thrombolytic agents play in the current management of peripheral vascular disease and acute stroke.

Catheter-directed thrombolysis - pharmacology - physiology - acute limb ischemia - stroke

REFERENCES

• 1 Tillett W S, Garner R L. The fibrinolytic activity of hemolytic streptococci.  J Exp Med. 1933;  58(4) 485-502
• 2 Tillett W S, Sherry S. The effect in patients of streptococcal fibrinolysin (streptokinase) and streptococcal desoxyribonuclease on fibrinous, purulent, and sanguinous pleural exudations.  J Clin Invest. 1949;  28 173-190
• 3 Tillett W S, Johnson A J, McCarty W R. The intravenous infusion of the streptococcal fibrinolytic principle (streptokinase) into patients.  J Clin Invest. 1955;  34(2) 169-185
• 4 Dotter C T, Rösch J, Seaman A J. Selective clot lysis with low-dose streptokinase.  Radiology. 1974;  111(1) 31-37
• 5 MacFarlane R G, Pilling J J. Fibrinolytic activity of normal urine.  Nature. 1947;  159(4049) 779
• 6 Sobel G W, Mohler S R, Jones N W et al.. Urokinase: an activator of plasma fibrinolysin extracted from urine.  Am J Physiol. 1952;  171 768-769
• 7 McNamara T O, Fischer J R. Thrombolysis of peripheral arterial and graft occlusions: improved results using high-dose urokinase.  AJR Am J Roentgenol. 1985;  144(4) 769-775
• 8 Keyt B A, Paoni N F, Refino C J et al.. A faster-acting and more potent form of tissue plasminogen activator.  Proc Natl Acad Sci U S A. 1994;  91(9) 3670-3674
• 9 Weaver F A, Comerota A J, Youngblood M, Froehlich J, Hosking J D, Papanicolaou G. Surgical revascularization versus thrombolysis for nonembolic lower extremity native artery occlusions: results of a prospective randomized trial. The STILE Investigators. Surgery versus Thrombolysis for Ischemia of the Lower Extremity.  J Vasc Surg. 1996;  24(4) 513-521, discussion 521–523
• 10 Ouriel K, Veith F J, Sasahara A A. TOPAS Investigators . Thrombolysis or peripheral arterial surgery: phase I results.  J Vasc Surg. 1996;  23(1) 64-73, discussion 74–75
• 11 Ouriel K, Veith F J, Sasahara A A. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators . A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs.  N Engl J Med. 1998;  338(16) 1105-1111
• 12 Lonsdale R J, Berridge D C, Earnshaw J J et al.. Recombinant tissue-type plasminogen activator is superior to streptokinase for local intra-arterial thrombolysis.  Br J Surg. 1992;  79(3) 272-275
• 13 Working Party on Thrombolysis in the Management of Limb Ischemia . Thrombolysis in the management of lower limb peripheral arterial occlusion—a consensus document.  Am J Cardiol. 1998;  81(2) 207-218
• 14 Comerota A J, Weaver F A, Hosking J D et al.. Results of a prospective, randomized trial of surgery versus thrombolysis for occluded lower extremity bypass grafts.  Am J Surg. 1996;  172(2) 105-112
• 15 Veith F J, Gupta S K, Ascer E et al.. Six-year prospective multicenter randomized comparison of autologous saphenous vein and expanded polytetrafluoroethylene grafts in infrainguinal arterial reconstructions.  J Vasc Surg. 1986;  3(1) 104-114
• 16 Clagett G P, Sobel M, Jackson M R, Lip G Y, Tangelder M, Verhaeghe R. Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  Chest. 2004;  126(3, Suppl) 609S-626S
• 17 Davies M G, Hagen P O. Pathophysiology of vein graft failure: a review.  Eur J Vasc Endovasc Surg. 1995;  9(1) 7-18
• 18 Braithwaite B D, Buckenham T M, Galland R B, Heather B P, Earnshaw J J. Thrombolysis Study Group . Prospective randomized trial of high-dose bolus versus low-dose tissue plasminogen activator infusion in the management of acute limb ischaemia.  Br J Surg. 1997;  84(5) 646-650
• 19 Semba C P, Bakal C W, Calis K A Advisory Panel on Catheter-Directed Thrombolytic Therapy et al. Alteplase as an alternative to urokinase.  J Vasc Interv Radiol. 2000;  11(3) 279-287
• 20 Rajan D K, Patel N H, Valji K CIRSE and SIR Standards of Practice Committees et al. Quality improvement guidelines for percutaneous management of acute limb ischemia.  J Vasc Interv Radiol. 2009;  20(7, Suppl) S208-S218
• 21 The International Study Group . In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin.  Lancet. 1990;  336(8707) 71-75
• 22 Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.  J Am Coll Cardiol. 1988;  12(6, Suppl A) 3A-13A
• 23 Swischuk J L, Smouse H B. Differentiating pharmacologic agents used in catheter-directed thrombolysis.  Semin Intervent Radiol. 2005;  22 121-129
• 24 Sato H, Weisel J W. Polymerization of fibrinogen-derived fragment X and subsequent rearrangement of fibers.  Thromb Res. 1990;  58(3) 205-212
• 25 Swischuk J L, Fox P F, Young K et al.. Transcatheter intraarterial infusion of rt-PA for acute lower limb ischemia: results and complications.  J Vasc Interv Radiol. 2001;  12(4) 423-430
• 26 Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.  N Engl J Med. 1995;  333(24) 1581-1587
• 27 Overgaard K, Sereghy T, Boysen G, Pedersen H, Diemer N H. Reduction of infarct volume and mortality by thrombolysis in a rat embolic stroke model.  Stroke. 1992;  23(8) 1167-1173, discussion 1174
• 28 Siesjö B K. Pathophysiology and treatment of focal cerebral ischemia. Part I: Pathophysiology.  J Neurosurg. 1992;  77(2) 169-184
• 29 Albers G W, Amarenco P, Easton J D, Sacco R L, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke.  Chest. 2001;  119(1, Suppl) 300S-320S
• 30 Albers G W, Amarenco P, Easton J D, Sacco R L, Teal P. American College of Chest Physicians . Antithrombotic and thrombolytic therapy for ischemic stroke.  Chest. 2008;  133(6, Suppl) 630S-669S
• 31 Sliwka U, Mull M, Stelzer A, Diehl R, Noth J. Long-term follow-up of patients after intraarterial thrombolytic therapy of acute vertebrobasilar artery occlusion.  Cerebrovasc Dis. 2001;  12(3) 214-219
• 32 Brandt T. Diagnosis and thrombolytic therapy of acute basilar artery occlusion: a review.  Clin Exp Hypertens. 2002;  24(7-8) 611-622
• 33 Fox T, Hamann G, Strittmatter M et al.. Local intraarterial fibrinolysis in vertebrobasilar thrombosis: prognostic criteria.  Cerebrovasc Dis. 1996;  6 186, Article 41
• 34 Cross III D T, Moran C J, Akins P T, Angtuaco E E, Diringer M N. Relationship between clot location and outcome after basilar artery thrombolysis.  AJNR Am J Neuroradiol. 1997;  18(7) 1221-1228
• 35 Lindsberg P J, Mattle H P. Therapy of basilar artery occlusion: a systematic analysis comparing intra-arterial and intravenous thrombolysis.  Stroke. 2006;  37(3) 922-928
• 36 Smith W S, Sung G, Starkman S MERCI Trial Investigators et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial.  Stroke. 2005;  36(7) 1432-1438